Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference 2018

SMi Group21 - 22 May 2018, London, UK.
SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London. The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs.

However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.

This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find new innovative solutions.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Justin Mason-Home, Director, HPAPI Project Services Limited

Key speakers include:

  • Ildikó Zeigler, Validation Expert, Gedeon Richter
  • Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer
  • Vincenzo De Sio, HPAPI Specialist, Cristália
  • Pascal Drago, Principal Technical Manager, Roche
  • Henri Motte, Head of Pilot Plant, UCB Pharma
  • Jeff Parry, Senior Scientist Manufacturability, AstraZeneca
  • Greg Sowell, Principal Scientific Manager, Genentech

Featured highlights:

  • Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner
  • Explore different containment methods and learn about which strategy best suits your needs
  • Evaluate the use of containment risk mitigation tools in early phase development
  • Learn how to manage and effectively and safely dispose of HPAPI, post-production waste
  • Discuss the most important regulations surrounding potent ingredients

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
https://www.smi-online.co.uk/pharmaceuticals/uk/Highly-Potent-Active-Pharmaceutical-Ingredients

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Chinese researchers report first lung stem cell tr…

A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first time, researchers have regenerated patients...

Pfizer receives Breakthrough Therapy designation f…

Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Dr...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Light-activated cancer drugs without toxic side ef…

Future cancer drugs that are activated by light and don’t cause the toxic side-effects of current chemotherapy treatments are closer to becoming a reality, thanks to new ...

New research suggests your immune system can prote…

After years of investigation, researchers at Johns Hopkins, the University of California, Davis, and the National Institute of Allergy and Infectious Diseases have discov...